20-F: Opthea Discontinues Wet AMD Program, Settles Funding

Opthea Limited has ceased development of its lead drug candidate, sozinibercept, for wet AMD after Phase 3 trial failures, settling a major funding agreement and initiating a strategic review for new therapeutic applications.

Summary

• Opthea's lead asset, sozinibercept, failed to meet primary endpoints in both its COAST and ShORe Phase 3 clinical trials for wet AMD in March 2025.
• Following the negative trial results, Opthea discontinued the development of sozinibercept for wet AMD.
• The company reached a binding agreement on August 19, 2025, to terminate the Development Funding Agreement (DFA) with DFA Investors, involving a cash payment of US$20 million and the issuance of 136,661,003 ordinary shares (9.99% of fully diluted share capital).
• Opthea has streamlined operations, reducing its workforce by 80% and its Board of Directors by over 50%, with 4 full-time employees remaining as of September 11, 2025.
• A full strategic review of the business is underway, focusing on reformulating its portfolio of drug candidates targeting VEGF-C and/or VEGF-D for other organ-mediated disorders.
• The company had a total comprehensive loss of US$162.8 million for the fiscal year ended June 30, 2025, and an accumulated loss of US$742.5 million as of June 30, 2025.
• Cash and cash equivalents were US$48.4 million as of June 30, 2025, and US$20 million as of August 20, 2025, after the DFA settlement.
• Current cash balance is expected to fund operations into the fourth calendar quarter of 2026, contingent on the success of the reformulation process and the nature/size of future clinical trials.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the complete failure of the lead product in Phase 3 trials, leading to program discontinuation, significant workforce reduction, and substantial accumulated losses. While a strategic pivot is planned, it is in very early stages with no guaranteed success, and the company faces 'substantial doubt about its ability to continue as a going concern'.

Positives

• The settlement of the Development Funding Agreement (DFA) resolves a significant financial liability and releases liens on company assets.
• The company is undertaking a strategic review to reformulate its drug candidates (VEGF-C and/or VEGF-D) for potential new therapeutic applications in other organs, indicating a pivot rather than complete cessation of R&D.
• Steps have been taken to apply for a patent to protect the use of OPT-302 in various new delivery methods, potentially creating new intellectual property value.

Negatives

• The lead product candidate, sozinibercept, failed to meet primary endpoints in both pivotal COAST and ShORe Phase 3 clinical trials for wet AMD.
• The company has discontinued the entire wet AMD development program for sozinibercept.
• Incurred a net loss of US$162.8 million for the fiscal year ended June 30, 2025, and has an accumulated loss of US$742.5 million.
• Workforce reduced by 80% and Board of Directors by over 50% following trial failures, indicating significant operational downsizing.
• Trading in ordinary shares on the ASX and ADSs on Nasdaq has been halted since the announcement of trial failures and remains suspended.
• The company faces substantial doubt about its ability to continue as a going concern due to significant losses and the need for additional capital.

Risks

• Inability to successfully reformulate drug candidates for new indications or continue as a going concern.
• Requirement for substantial additional capital, which may not be available on favorable terms or at all, leading to potential dilution for shareholders.
• Future clinical trials for new product candidates may be delayed, more costly than anticipated, or fail to demonstrate desired safety and efficacy.
• Potential for undesirable side effects or adverse events in future product candidates, delaying or preventing regulatory approval.
• Expensive, time-consuming, and uncertain marketing approval process for any future product candidates.
• Difficulties in enrolling patients in future clinical trials, similar to past experiences.
• Substantial competition from other biopharmaceutical companies, potentially leading to others commercializing competing products more successfully.
• Negative impact from health epidemics, macroeconomic conditions, or geopolitical conflicts on business operations, manufacturing, and clinical trials.
• Disruptions at regulatory agencies (e.g., FDA) due to funding shortages or other factors, delaying product development and approval.
• Changes in U.S. healthcare law, such as the Inflation Reduction Act, or other countries' policies, impacting pricing, reimbursement, and profitability.
• Reliance on third-party manufacturers and CROs, who may not perform satisfactorily or meet deadlines, leading to delays and increased costs.
• Inability to attract, integrate, manage, and retain qualified personnel or key employees.
• Inability to obtain and maintain intellectual property protection for products and technologies, or challenges to existing IP rights.
• Potential for product liability lawsuits, leading to substantial liabilities and commercialization limitations.
• Exposure to economic, political, and regulatory risks associated with international operations.
• Risk of being classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. holders.
• Potential for securities litigation due to stock price volatility.

Future Outlook

The company's future outlook involves a full strategic review to reformulate its portfolio of drug candidates targeting VEGF-C and/or VEGF-D for use in treating other organ-mediated disorders. This includes applying for new patents for various delivery methods. Future clinical trials are expected to be outsourced to third-party providers. The current cash balance is projected to fund operations into the fourth calendar quarter of 2026, but this estimate is dependent on the success of the reformulation process and the scope of future clinical trials.

Management Comments

• The management team and Board of Directors, in consultation with the DFA Investors, determined that discontinuing the development of sozinibercept in wet AMD was the most appropriate course of action for patients, shareholders, and other stakeholders.
• The company's goal is to continue targeting Vascular Endothelial Growth Factors (VEGF) and to reformulate its anti-VEGF compounds, including OPT-302, to treat diseases known to be mediated by VEGF-C and/or D in other organs.
• Jeremy Levin is acting as Chief Executive Officer effective September 1, 2025, following Fred Guerard's departure, and will fulfill the roles and responsibilities of the outgoing CEO as a consultant.

Industry Context

The biopharmaceutical industry is intensely competitive, characterized by rapid innovation and significant technological advancements. Opthea's shift from wet AMD development to reformulating VEGF-C/D compounds for other indications reflects the high-risk nature of drug development, where lead candidates can fail in late-stage trials. The industry also faces increasing scrutiny over drug pricing and reimbursement, as well as evolving data privacy and security regulations, which add complexity and cost to operations. The company's reliance on third-party manufacturers and CROs is a common industry practice but introduces additional risks.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any material legal proceedings.

Related Party Transactions

• Ocelot, Launch Tx, Carlyle, and Saama Technologies became related parties following Anshul Thakral's appointment as a Director on June 7, 2023. Anshul Thakral resigned on June 2, 2025, so these entities are no longer related parties at year-end.
• Purchases of service from Ocelot amounted to US$32.793 million in FY2025 (US$24.699 million in FY2024, US$0 in FY2023).
• Purchases of service from Launch Tx amounted to US$9.900 million in FY2025 (US$2.700 million in FY2024, US$0.900 million in FY2023).
• Purchases of service from Mr. Lawrence Gozlan (a director) for consultancy fees related to capital raising amounted to US$0.275 million in FY2025 (US$0 in FY2024, US$0 in FY2023).
• Purchases of service from Saama Technologies amounted to US$0.121 million in FY2025 (US$0.343 million in FY2024, US$0 in FY2023).
• Amounts owed to Ocelot related to the DFA were US$141.554 million in FY2024 (US$85.660 million in FY2023). This liability was settled in August 2025.
• Amounts owed to Launch Tx were US$2.250 million in FY2025 (US$0.900 million in FY2023).
• Amounts owed by Launch Tx (prepayments) were US$3.150 million in FY2024.
• Amounts owed by Saama Technologies (prepayments) were US$0.024 million in FY2024.
• A Consultancy Agreement with Mr. Lawrence Gozlan for up to US$300,000 was entered into on August 28, 2023, for services related to the 2023 Equity Offering, with US$125,000 in transaction costs paid in FY2024.
• A second Consultancy Agreement with Mr. Lawrence Gozlan for up to US$275,000 was entered into on September 19, 2024, for capital raising services, with US$275,000 in costs included in administrative expenses for FY2025.

Stakeholder Impact

• Shareholders: Significant negative impact due to the failure of the lead product, suspension of trading, substantial accumulated losses, and dilution from the DFA settlement equity issuance. Future value depends entirely on the success of the strategic review and new drug candidate development.
• Employees: Severe negative impact due to an 80% workforce reduction following the discontinuation of the wet AMD program.
• DFA Investors: Received a US$20 million cash payment and a 9.99% equity stake in the company as part of the settlement, resolving their funding agreement.
• Customers/Patients: The discontinuation of sozinibercept for wet AMD means this potential treatment will not be available, impacting patients who might have benefited from it.

Next Steps

• Complete a full strategic review of the business, focusing on reformulating the portfolio of drug candidates targeting VEGF-C and/or VEGF-D for other organ-mediated disorders.
• Apply for a patent to protect the use of OPT-302 in various new delivery methods.
• Conduct clinical trials for any future drug candidates in treating VEGF-C and/or VEGF-D mediated disorders in other organs, expected to be outsourced to third-party providers.
• Engage with listing authorities regarding the ongoing suspension of trading in shares on the ASX and ADSs on Nasdaq.
• If reformulation is not viable, consider a return of capital to shareholders and ceasing Group operations.

Key Dates

Recommendation

The company's lead product candidate failed in Phase 3 trials, leading to the complete discontinuation of its primary development program. This has resulted in significant financial losses, a substantial accumulated deficit, and an auditor's report raising 'substantial doubt about the Company's ability to continue as a going concern.' While a strategic review is underway to pivot to new indications, this is a high-risk, early-stage endeavor with no guaranteed success. The stock's trading is currently suspended, and the future viability of the company is highly uncertain, making it a strong sell for any existing holdings.

Keywords

Biopharmaceutical, VEGF-C, VEGF-D, Drug Development, Clinical Trials, Strategic Review, Biotechnology, Ophthalmology, Wet AMD, Sozinibercept, OPT-302, SEC Filing, Financial Reporting, Corporate Governance, Risk Management